Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Eli Lilly -- Ignore unavailable to you. Want to Upgrade?

To: Barron Von Hymen who wrote (183)	4/28/1998 12:50:00 AM
From: LoLoLoLita	Respond to of 641

Barron, I don't think that there is anything fortuitous about the use of Evista to reduce breast cancer risks and heart disease. LLY has known about the potential for these uses for quite some time. It's been widely reported. Seeking FDA approval of Evista for preventing osteoporosis first, and the other uses later, was a smart move on their part because the demonstration of osteo-protective effects can be done with clinical trials of shorter duration than the trials that would be needed for the other uses. Osteo-protective effects can be readily measured with various clinical tests that measure bone mass, calcium levels, etc. All without the need to wait a minimum of several years to see what the incidence of breast cancer and heart disease are in the study populations. Changing the subject slightly. Just right after the NCI study results on tamoxifen were published, April 6 I believe, there was an article in the local newspaper on Kaua'i, The Garden Island, about the possibility that raloxifene could provide similar benefits, albeit with a much better side effect profile. It was a locally-generated news story from Honolulu, and I recall that they got some information from someone at an Oahu cancer research center or hospital on the breast cancer risk reduction associated with raloxifene. The man they interviewed gave an effectiveness of approximately 70%, greatly exceeding the 45% reported by the NCI for tamoxifen. This seemed very strange that a medical researcher would report such findings prior to publication in scientific journals or submission to the FDA. So I just ignored it, and didn't save the article. Does anyone here know if LLY has raloxifene in Phase III studies for breast cancer prevention at an Oahu research facility? Thanks. David